Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.

In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) ...

This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...

Lotte Biologics CEO James Park aims to secure ADC orders at U.S. plant this year Lotte Biologics new leadership seeks to ...

New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on 'Advancing as a Global CDMO Leader' ...

The Court of Appeal (CoA) of the Unified Patent Court (UPC) clarified the legal standard for correcting obvious type inaccuracies in patent ...

PORTLAND, IA, UNITED STATES, January 28, 2025 /EINPresswire / -- According to the report, the global biosimilars <a target=_blank href= ...

Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Antibodies are a major component of adaptive immunity against ... from which the sequences are extracted and run through Stitch to select the top-scoring V-gene and construct a placeholder sequence ...

PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) ...